방사선생물학

본문글자크기
  • [Cancer Res Treat.] Combination Treatment of Stereotactic Body Radiation Therapy and Immature Dendritic Cell Vaccination for Augmentation of Local and Systemic Effects.SBRT와 미성숙 DC백신의 병용치료에 의한 국소 및 시스테믹 항암반응에 대한 연구

    DIRAMS / 최철원*

  • 출처
    Cancer Res Treat.
  • 등재일
    2019 Apr
  • 저널이슈번호
    51(2):464-473. doi: 10.4143/crt.2018.186. Epub 2018 Jun 6.
  • 내용

    바로가기  >

    Abstract
    PURPOSE:
    The purpose of this study was to investigate the efficacy of stereotactic body radiation therapy (SBRT) as a tumor-associated antigen (TAA) presentation method for dendritic cell (DC) sensitization and evaluate its effect in combination with immunotherapy using an intratumoral injection of immature DCs (iDCs).

    Methods and Materials:
    CT-26 colon carcinoma cell was used as a cancer cell line. Annexin V staining and phagocytosis assays were performed to determine the appropriate radiation dose and incubation time to generate TAAs. BALB/c mice were used for in vivo experiments. Cancer cells were injected into the right legs and left flanks to generate primary and metastatic tumors, respectively. The mice were subjected to radiation therapy (RT) alone, intradermal injection of electroporated DCs alone, or RT in combination with iDC intratumoral injection (RT/iDC). Tumor growth measurement and survival rate analysis were performed. Enzyme-linked immunospot and cytotoxicity assays were performed to observe the effect of different treatments on the immune system.

    RESULTS:
    Annexin V staining and phagocytosis assays showed that 15 Gy radiation dose and 48 hours of incubation was appropriate for subsequent experiments. Maximum DC sensitization and T-cell stimulation was observed with RT as compared to other TAA preparation methods. In vivo assays revealed statistically significant delay in the growth of both primary and metastatic tumors in the RT/iDC group. The overall survival rate was the highest in the RT/iDC group.

    CONCLUSION:
    The combination of SBRT and iDC vaccination may enhance treatment effects. Clinical trials and further studies are warranted in the future.

     


    Author information

    Choi CW1, Jeong MH2, Park YS3, Son CH3, Lee HR3, Koh EK3
    1
    Department of Radiation Oncology, Dongnam Institute of Radiological & Medical Sciences, Busan, Korea.
    2
    Department of Microbiology, Dong-A University College of Medicine, Busan, Korea.
    3
    Department of Research Center, Dongnam Institute of Radiological & Medical Sciences, Busan, Korea.

  • 키워드
    Immature dendritic cells; Immunotherapy; Stereotactic body radiotherapy; Tumor antigen
  • 덧글달기
    덧글달기
       IP : 3.209.56.116

    등록